SCTbio

SCTbio does not publish its own clinical results as it operates primarily as a contract development and manufacturing organization. It has extensive experience supporting the manufacture of autologous cell therapies, viral vectors, and ATMPs under GMP conditions. The company’s expertise includes technology transfer, process development, fill & finish operations, quality control/release testing, storage/logistics management—including an established network of over 150 qualified apheresis centers in Europe and the USA—and regulatory support throughout the product lifecycle. Its team has more than a decade of experience in the field through legacy work with SOTIO Group.